Pfizer to file Sutent cancer drug in August

MarkCotton

NEW YORK (MarketWatch) -- Pfizer
pfe
said Thursday it plans to file its investigational new drug Sutent, to treat metastatic renal cell and gastrointestinal stromal cancer during August. The drug company said it was issuing the statement to address recent analyst comments regarding the timing of the regulatory filing. On Thursday, Pfizer's stock fell 1.2% to $27.06.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.